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ABSTRACT 
 
Polyglutamine disorders are a class of nine inherited neurodegenerative disorders caused by expansion of 
a CAG repeat within otherwise unrelated genes. Polyglutamine expansion causes aberrant protein 
misfolding that leads to formation of protein aggregation and neuronal loss. Machado-Joseph disease 
(MJD) is included in this group of disorders, being caused by expansion of a CAG tract in the C-terminal 
region of the protein Ataxin-3 (ATXN3). MJD is characterized by the formation of intranuclear neuronal 
inclusions (NIs) and nervous system dysfunction, but the mechanism of this ATXN3- mediated dysfunction 
is still unsolved. So far, some symptoms can be controlled with specific treatments, but there is no 
effective therapy for MJD. 
Our team previously established a new MJD mouse model expressing human ATXN3 with 135 glutamines 
– CMVMJD135 – that presents phenotypic, pathologic and genetic similarities with the human disorder, 
namely several reliable and quantifiable phenotypic markers that can be used in therapeutic trials.  The 
NFIs are a pathological hallmark of this disease and have been found in this mouse model, as happens in 
human patients. Many studies related with therapeutic targets in polyQ diseases reveal phenotype 
amelioration without mention to neuropathology, namely inclusion load. Immunohistochemistry was 
performed to evaluate the relevance of inclusion load assessment in pre-clinical trials using a mouse model 
of MJD. We evaluated the utility of using this biomarker in therapeutic trials using three pharmacological 
compounds: creatine, 17-DMAG and valproic acid. We have found a significant reduction in inclusion load 
in the lateral reticular nucleus (LRT) region and a tendency towards a reduction of neuronal inclusions in 
the facial nuclei (7N) region of CMVMJD135 mice treated with creatine. The chronic treatment with 
creatine also lead to an amelioration of the motor phenotype observed in these animals, namely an 
increase in muscle strength and a better motor performance in the motor swimming test. 
Another compound, 17-DMAG did not show any differences between treated and non-treated transgenic 
mice group regarding NIs in the LRT and 7N brain regions, although a phenotype amelioration was 
observed in several behavioral paradigms. CMVMJD135 mice treated with Valproic acid exhibit a tendency 
towards a reduction of neuronal inclusions load in the LRt but no reduction in inclusion load in the 7N 
brain region. Globally our results suggest that there is no direct correlation between the aggregate load in 
these brain regions of the CMVMJD135 mice and the phenotypic effect observed upon chronic treatment 
with different compounds. 
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RESUMO 
 
As doenças de poliglutaminas são um conjunto de doenças neurodegenerativas hereditárias causadas pela 
expansão de um tripleto de CAG nas regiões codificantes dos respetivos genes causadores. A expansão do 
tripleto CAG leva à formação de proteínas que possuem uma expansão anormal de uma sequência de 
poliglutamina, causando o seu desarranjo conformacional, podendo estas proteínas agregar e conduzir à 
morte neuronal num estadio mais avançado da doença. A doença de Machado-Joseph (DMJ) inclui-se 
neste grupo de doenças, sendo caracterizada por uma expansão de glutaminas localizada na região C-
terminal da proteína envolvida na DMJ, a ataxina-3 (ATXN3). São características comuns a todas as 
doenças de poliglutaminas a presença de inclusões proteicas intranucleares nos neurónios (IINs) e a 
disfunção neuronal. No entanto, permanece por esclarecer a relevância das IINsna patogénese da DMJ. 
Até à data, embora seja possível controlar alguma da sintomatologia observada nos doentes, não existe 
um tratamento eficaz para a DMJ.  
No presente estudo, utilizou-se um modelo de ratinho para a DMJ que foi previamente gerado no nosso 
laboratório, e que apresenta várias características semelhantes às da doença humana, quer a nível 
genético e fenotípico, quer a nível neuropatológico. Este modelo apresenta características passíveis de 
quantificação, permitindo o seu uso em ensaios pre-clínicos. As IINs são uma característica chave da DMJ 
e foram detetadas nos cérebros deste modelo. Vários ensaios pré-clínicos recorrendo a várias estratégias 
terapêuticas e a diferentes modelos de ratinho, demonstram uma melhoria do fenótipo observado em 
cada modelo, no entanto, a referência ao efeito dos compostos utilizados na quantidade de agregados 
proteicos não é clara. Numa tentativa de esclarecer a relação entre a melhoria no fenótipo e a quantidade 
de IINs nos cérebros dos ratinhos CMVMJD135, foi efetuado um estudo de quantificação das IINs em 
algumas regiões do cérebro relevantes na DMJ, após o tratamento crónico dos ratinhos com três 
compostos: creatina, 17-DMAG e ácido valpróico. Foi possível observar uma redução significativa da 
densidade de IINs no LRT e uma tendência para o mesmo resultado no 7N nos animais tratados com 
creatina, quando comparados com animais veículo.  Assim, e tendo em conta que a creatina apresentou 
um efeito benéfico nos sintomas motores e também melhorou a perda de força muscular dos animais 
transgénicos, pode dizer-se que existe uma correlação direta entre densidade de IINs positivos para a 
ATXN3 e o efeito positivo no fenótipo destes animais. Em contraste, apesar de o 17-DMAG ter tido um 
efeito positivo no fenótipo dos animais, não foi observada uma redução da densidade de IINs nos núcleos 
LRT e 7N. Por fim, o ácido valpróico demonstrou ter um efeito muito ligeiro e tardio no fenótipo dos 
animais, não tendo sido observada uma redução significativa da densidade dasIINs nas áreas acima 
referidas. Globalmente, estes resultados demonstram que não existe uma relação direta entre densidade 
de IINs nestas regiões e a melhoria a nível fenotípico dos animais transgénicos para a DMJ. 
X 
 
 
 
 
XI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
XII 
 
XIII 
 
 
 
 CONTENTS 
Abbreviations List .................................................................................................................... XV 
Figures and Tables ................................................................................................................. XIX 
1. Introduction ...................................................................................................................... 1 
1.1. Polyglutamine (PolyQ) diseases ............................................................................. 3 
1.2. Polyglutamine pathogenic mechanisms ................................................................. 4 
1.2.1. Protein aggregation and misfolded proteins affect proteostasis ..................... 5 
1.2.2.Transcriptional deregulation ......................................................................... 5 
1.2.3. Mitochondrial impairment/oxidative stress .................................................. 6 
1.3.Machado-Joseph disease ........................................................................................ 7 
1.3.1. History........................................................................................................ 7 
1.3.2. MJD clinical symptoms and sub-types ......................................................... 7 
1.3.3. MJD pathology ............................................................................................ 8 
1.3.4.MJD genetics ............................................................................................... 9 
1.3.5.MJD protein –Ataxin3 ................................................................................... 9 
1.4.Animal models (mouse) for the MJD ..................................................................... 10 
1.5.Therapeutic strategy of pre-clinical trial drug ......................................................... 11 
1.5.1.Mitochondrial stabilization and reduction of oxidative stress ........................ 11 
1.5.2.Clearance machinery: Chaperone related protein turnover .......................... 13 
1.5.3.Transcriptional regulation ........................................................................... 13 
1.6.Aim of the thesis .................................................................................................. 15 
2. Methods and Materials .................................................................................................... 17 
2.1.Animals................................................................................................................ 19 
2.2.Genotyping and maintanence ............................................................................... 19 
XIV 
 
 
 
2.3.Immunohistochemistry ......................................................................................... 19 
3. Results ........................................................................................................................... 21 
3.1.CMVMJD135 mice treated with creatine exhibit reduced abundance of intranuclear 
ataxin-3 inclusion in the lateral reticular nuclei and facial nuclei of the brain……………………23 
3.2.CMVMJD135 mice treated with 17-DMAG did not exhibit a reduction in intranuclear 
ataxin-3 inclusion in the lateral reticular nuclei or facial nuclei of the brain ........................... 24 
3.3. CMVMJD135 mice treated with Valproic acid (VPA) showed less intranuclear 
inclusion load than the saline-treated group ........................................................................ 26 
4.Discussion ........................................................................................................................... 29 
 4.1.Future work .............................................................................................................. 34 
5.Conclusion .......................................................................................................................... 35 
6.References .......................................................................................................................... 39 
 
 
 
 
 
 
XV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ABBREVIATIONS
XVI 
 
XVII 
 
 
 
LIST OF ABBREVIATIONS 
 
 
AR – Androgen receptor 
ATXN3 – Ataxin-3 gene 
ATXN3 – Ataxin-3 protein 
ATP – Adenosine triphosphate 
a.a. –Aminoacid 
bp – Base pairs 
CNS – Central Nervous System 
cDNA – complementary DNA 
CMVp – Cytomegalovirus promoter 
C. elegans – Caenorhabditis elegans 
CAG – Trinucleotide codon for 
Glutamine 
CREB -cyclic AMP responsive element binding 
protein 
CBP – CREB binding protein 
cyt c – Cytochrome c 
CHIP- (C-terminus of Hsp70-interacting protein) 
Ca2+ - calcium ion 
DNA – Deoxyribonucleic acid 
 
DRPLA – Dentatorubral-Pallidoluysian 
Atrophy 
DAB – 3, 34-biiaminobenzidine 
DUB- Deubiquitinating Enzymes  
ER – Endoplasmic reticulum 
HD – Huntington's Disease 
HDAC – Histone Deacetylase 
HSR- Heat-shock response  
Hdj2 – Constitutive form of 40-kDa 
heat-shock protein 
Hsp – Heat shock protein 
HAT – Histone Acetylase 
Htt – Huntingtin Protein 
H3 – Histone 3 
H4 – Histone 4 
IHC-Immunohistochemistry 
kDa – KiloDalton(s) 
kb – kilobase 
LD- lateral dentate nuclei 
 
 
 
 
XVIII 
 
 
 
 
MJD – Machado-Joseph Disease 
MPT- mitochondrial permeability transition 
mtDNA – mitochondrial DNA 
MT – Mitochondria 
n – Number of samples in the study 
NI – Neuronal Inclusion 
OH8dG – 8 hydroxydeoxyguanosine 
pCAF – Protein-associated factor 
PCR – Polymerase Chain Reaction 
PFA – Paraformaldehyde 
Pn – Pontine Nucleus 
polyQ – Polyglutamine 
Q – Glutamine 
RNA – Ribonucleic acid 
ROS – Reactive Oxygen Species 
SCA – Spinocerebellar Ataxia 
SN – Substantia Nigra 
 
SMBA – Spinal and Bulbar Muscular 
Atrophy 
SAHA – Suberoylanilide Hydroxamic 
Acid 
SOD – Superoxide dismutase 
SP1 – Specificity Protein 1 
TFs- Transcription factor 
TBP- TATA-Binding Protein 
Th- thalamus 
TAFII130 – TBP-associated factor 
UIM – Ubiquitin-interacting motifs 
UPS – Ubiquitin-proteasome system 
Ub- ubiquitin 
Ve- vestibular nucleus 
WT- Wild type 
μm – Micrometer 
 
 
 
 
 
 
 
 
 
 
 
XIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURES AND TABLES 
XX 
 
XXI 
 
 
 
FIGURES  AND  TABLES 
 
Figure 1: mechanism of polyQ pathogenesis...................................................................... 4 
 
 
Figure 2: Brain region affected in MJD............................................................................... 8 
 
 
Figure 3: Intranuclear ATXN3 inclusion load in CMVMJD 135 mice treated with a normal diet 
and 2% creatine supplementation.................................................................................... 24 
 
Figure 4: Intranuclear ATXN3 inclusion load in CMVMJD 135 mice treated with vehicle (saline) 
and 17-DMAG………….................................................................................................... 25  
 
 
Figure 5: ATXN3 intranuclear inclusion load in CMVMJD 135 mice treated with vehicle and 
VPA. ............................................................................................................................ 27 
 
 
 
Table 1: Molecular features of Polyglutamine disease…….................................................... 3 
 
 
Table 2: Mouse models of MJD………............................................................................... 10 
 
Table 3: Therapeutic rationale of our pre-clinical trials...................................................... 16 
 
Table 4: Illustration of experimental animal..................................................................... 19 
 
Table 5: A brief summary of the results obtained for the three compounds........................ 27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
XXII 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. INTRODUCTION 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
1. INTRODUCTION 
 
1.1. Polyglutamine (PolyQ) diseases 
Polyglutamine diseases are genetic disorders caused by an expansion of a trinucleotide (CAG) within the 
coding region of the corresponding genes. The first disease described was spinal bulbar muscular atrophy 
(SBMA) (1). Eight other disorders including HD, dentatorubropallidoluysian atrophy (DRPLA), and six types 
of spinocerebellar ataxia (SCA1, 2, 3, 6, 7, and 17) (2) have since been identified as associated with polyQ 
expansions (Table-1). With the exception of SBMA, polyQ disorders are autosomal dominant, completely 
penetrant and progressive. To date, the normal function of many of the genes causing polyQ disorders 
remains unclear and apart from the polyQ tract, these proteins share no homologies, are unrelated to each 
other, vary in size and contain the glutamine segment at distinct locations within the protein sequence.  
Commonly these proteins are expressed in central nervous system and peripheral tissues. In addition, 
PolyQ repeats can expand or  contract , but expanded polyQ repeats show an inverse correlation between 
the number of CAG repeats and age of the disease onset (3-5), and a correlation was observed between 
the length of the CAG repeats and the number of inclusions in disease brain (6, 7). 
Table-1: Molecular features of Polyglutamine disease (adapted from reference # 8) 
Disease 
Mutated 
gene 
Gene 
product 
Protein function Protein localization 
Normal 
(CAG)n 
Expanded 
(CAG)n 
 
Huntington Disease 
 
HD 
 
Huntingtin 
Signaling transport, 
transcription 
 
Cytoplasmic 
 
6-35 
 
36-121 
Spinocerebellar ataxia type 1 
(SCA1) 
ATXN1 Ataxin-1 Transcription Nuclear in neurons 6-39 39-83 
Spinocerebellar ataxia type 2 
(SCA2) 
ATXN2 Ataxin-2 RNA metabolism Cytoplasmic 14-31 32-200 
Spinocerebellar ataxia type 3 
(SCA3, Machado joseph 
disease) 
ATXN3 Ataxin-3 De-ubiquitlating activity Cytoplasmic and nuclear 12-40 54-86 
Spinocerebellar ataxia type 6 
(SCA6) 
CACNA1A CACNA1A 
Voltage-dependent 
calcium channel subunit 
alpha-1A 
Cell membrane 4-20 20-30 
Spinocerebellar ataxia type 7 
(SCA7) 
ATXN7 Ataxin-7 Transcription Nuclear 4-35 37-306 
Spinocerebellar ataxia type 
17 (SCA17) 
TBP TBP Transcription factor Nuclear 25-42 47-63 
Dentatorubral-pallidoluysian 
atrophy (DRPLA) 
DRPLA Atrophin-1 Transcriptional regulator Cytoplasmic 3-35 49-88 
spinal and bulbar muscular 
atrophy (SBMA, Kenedy 
disease) 
AR 
Androgen 
receptor 
Steroid hormone 
receptor 
Nuclear, cytoplasmic 9-36 38-62 
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1.2 Polyglutamine pathogenic mechanisms 
Several cellular and molecular mechanisms have been implicated in polyglutamine toxicity, most of which 
suggest that the expanded polyQ tract confers a toxic gain-of-function to the mutant proteins. Rarely, it has 
also been associated with loss-of-function mechanisms of the disease-specific proteins, which is the case of 
the silenced or knock out ataxin-3. The pathogenic mechanism for all polyQ diseases is believed to involve 
the  protein folding machinery and aggregation process  Transcriptional deregulation, mitochondrial 
dysfunction, altered calcium homeostasis, cytoskeletal abnormalities, defects in axonal transport and 
synaptic transmission  have also been associated to pathogenesis. In the pre-clinical trials included in this 
thesis, we focus on three of these hypotheses: i) Protein aggregation and misfolded proteins affect 
proteostasis, ii) Transcriptional deregulation, iii) Mitochondrial impairment. 
 
Figure 1. Mechanisms of polyglutamine pathogenesis (adapted from reference# 9) The pathogenic process (red arrows) begins with the synthesis of expanded 
polyQ tract mutant protein. The expanded polyQ tract alters the native conformation of the protein, which can be modulated by the presence of molecular 
chaperones and co-chaperones. Usually some part of abnormally folded protein is ubiquitylated (Ub) and degraded via the proteasome and another portion is 
exposed to lysosomal-dependent proteolysis. In the pathogenic condition, cleavage of the abnormally folded mutant protein produces polyQ-containing fragments 
that favor the aggregation process. The mutant proteins shift from a monomeric random coil or β-sheet into oligomeric β-sheets and eventually into insoluble 
aggregates. Some of these species might contribute to pathology through ubiquitin-proteasome system (UPS) impairment, mitochondrial dysfunction and/or 
dysregulation of calcium homeostasis and transcriptional deregulation. Mutant proteins located in cytoplasm and nucleus. Presence in the nucleus seems to be 
key for pathogenesis. To control pathogenesis, several efforts have been made to reestablish cellular proteostasis (green arrows) such as mutant gene silencing 
and transcriptional modulation with HDAC inhibitors, blocking cleavage and aggregation, restoration of the quality control machinery and improving neuronal 
function and survival (neuroprotection). 
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1.2.1 Protein aggregation and misfolded proteins affect proteostasis 
Although protein aggregation is thought to be a main hallmark of many neurodegenerative diseases, the 
role of aggregates in neurodegeneration is not well elucidated. Formation of highly stable β-sheet structures 
and their subsequent stabilization by intermolecular interactions underlies the formation of oligomers and 
protein aggregates (10, 11). These aggregates were initially found in patients’ post-mortem brains and in 
the late 1990s they were also found in the brain of a HD mouse model (12). Even after two decades from 
their discovery in animal models, it is still controversial whether these aggregates are toxic or protective. 
Arrasate and colleagues suggested that in HD, Nuclear Inclusions (NI) or aggregates could provide 
protection to the neuronal cells, by stacking the toxic mutant proteins (13). On the contrary, protein 
aggregates have also been referred to harm neurons by affecting their proteostasis (8). Once misfolded, the 
mutant proteins are converted into insoluble aggregates which are resistant to proteolysis and they 
accumulate in the cell. In fact, soluble aggregates are shown to be efficiently cleared by the proteasomes 
(14). The mutated aggregated proteins interact with other cellular components, such as ubiquitin, ubiquitin-
like proteins, proteasome subunits, molecular chaperones and other polyQ-containing proteins and disturb 
cellular homeostasis, causing a decline in proteostasis (8, 15-17). As a consequence, variety of normal 
cellular functions such as, mitochondrial dysfunction, oxidative stress, transcriptional abnormalities, 
clearance machinery impairment, excitotoxicity, or apoptotic pathways are affected (18, 19). The polyQ 
aggregates are thought to impair the function of the proteasome and interfere with the degradation of other 
proteins (20, 21). Proteasome inhibition might increase the intracellular load of misfolded, oxidized, or 
otherwise damaged proteins, thereby causing neuronal toxicity. So, activation of molecular chaperones or 
autophagy induction are attractive therapeutic strategies to increase clearance, overcoming the chaperone 
machinery and/or the ubiquitin proteasome system impairment (22). These two pathways are involved in 
misfolded protein degradation, and accelerating the degradation of the mutated protein aggregates is 
proven to produce beneficial effects in MJD and other polyQ diseases. 
 
1.2.2 Transcriptional deregulation 
Another unifying feature of polyQ disorders is transcriptional dysregulation (23-25).  More than 20 reported 
interactors of polyglutamine disease associated-proteins are known to be involved in transcriptional 
regulation (24), affecting DNA methylation, histone acetylation and RNA modification. (26) The 
transcriptional co-activator CBP possesses HAT (histone acetyltransferase) activity and interacts with 
numerous transcription factors. Inhibition of HAT activity of CBP could lead to hypo-acetylation of histone 
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and suppress gene expression. Normally, the equilibrium of histone acetylation/deacetylation is controlled 
by histone acetyltransferases and deacetyltransferases (HDACs). Acetylation of histones relaxes the DNA 
structure and promote transcription, whereas hypoacetylation represses gene activity (27). PolyQ proteins 
by interacting with transcription regulators inhibit their acetyltransferase activity and diminish gene 
expression. In fact, Drosophila and mouse models of HD, treated with HDAC inhibitors showed 
amelioration in the disease phenotype with increased histone acetylation and consequent transcription 
activation and decrease cell degeneration (28-30). 
The mutant ataxin-3 protein abnormally interacts with transcription factors (TFs) such as TATA-Binding 
Protein (TBP), CREB (cyclic AMP responsive element binding protein) Binding Protein (CBP), Specificity 
Protein 1 (SP1) and TAFII130 (which encodes a TBP-Associated Factor) (24, 31). Overexpression of some 
of these transcription regulator proteins was shown to overcome polyQ toxicity, both in vitro for MJD, 
SBMA, and HD cellular models (32, 33) and in vivo in a Drosophila polyQ model (25), suggesting the 
transcriptional deregulation role of ataxin-3 in polyQ disease pathogenesis. 
 
1.2.3 Mitochondrial impairment/oxidative stress 
Numerous studies and observation of post-mortem brain of HD led to the proposal that mitochondrial 
impairment may contribute to the pathogenesis of polyQ diseases. The mitochondrial respiratory chain is 
one of the major sources of free radicals in human and these free radicals destroy cellular 
macromolecules, including DNA, lipids and proteins (34). Mitochondrial dysfunction in polyQ diseases 
could impair respiration; produce stress-induced mitochondrial depolarization, increase ROS production 
there by causing oxidative damage and abnormal energy metabolism that leads to decreased ATP 
production and increased apoptosis (35, 36). Mitochondrial dysfunction is directly or indirectly linked with 
other mechanisms, like transcriptional deregulation of nuclear-encoded mitochondrial proteins, Ca2+ 
handling impairment and trafficking deficits (22). A gradual or dramatic decline in the energy supply due to 
mitochondrial impairment leads to the release of proapoptotic factors, particularly cytochrome c and initiate 
an apoptotic cascade, contributing to necrotic cell death. Furthermore, while the intracellular Ca2+ 
concentration and Ca2+ signaling are necessary to maintain the normal cellular function of astrocytes and 
microglia cells (37), excessive Ca2+ accumulation also trigger apoptotic cascade in the cell. 
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1.3 Machado-Joseph disease (MJD) 
1.3.1 History 
MJD was initially described in 1972 in a Portuguese ancestor from the Azores Islands named William 
Machado, by Nakano and collaborators, as an autosomal dominant ataxia and they named it as Machado 
disease (38). In the same year, through his study of the Thomas family, Woods and Schaumburg entitiled 
this disease as Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia (39). Later, Antone 
Joseph’s family (Portuguese ethnic background, various Azores Islands) was reported to have a particular 
type of autosomal dominant hereditary ataxia in 1975, by Rosenberg and colleagues, and they designated 
it as Joseph disease (40). In 1978, Andrade and Coutinho undertook extensive studies in a large number 
of families in the Azores islands, and in the 1980 Coutinho research team concluded Machado and Joseph 
disease were same disorder, with a high clinical variability, and named it as Machado-Joseph disease or 
MJD (41-43). Finally, in the years 1983-84, the disease unification was achieved by Rosenberg and 
Barbeau who examined several patients and found siblings presenting different types of MJD. MJD has 
since then been described in non-Azorean families from various countries (44, 45). At present, MJD, also 
called spinocerebellar ataxia type 3 (SCA3) can be defined as a late onset, autosomal dominant, 
progressive neurodegenerative disorder (46, 47). The disease prevalence in Portugal is of 3.1:100.000 
habitants, including a total of 108 MJD families (48). 
 
1.3.2 MJD clinical symptoms and sub-types 
This progressive neurodegenerative disorder is characterized by ataxia, weakness in the arms and legs, 
spasticity, speech and swallowing difficulty, impaired involuntary eye movements and dystonia. Motor 
function is highly affected in MJD. Some patients have twitching of the face or tongue, or bulging eyes (42, 
45, 49, 50). Even though it is very difficult to identify the MJD types, they could be partially justified by the 
phenotypic variability of MJD, organization of the disease sub-types, onset of age and major disorder 
symptoms. MJD type I is early age at onset (10-30 years of age), faster progression and more severe 
pyramidal and extra-pyramidal signs. MJD type II is the most frequent, and is characterized by intermediate 
age at onset (20-50 years of age) and a moderate progression rate, with patients exhibiting mainly ataxia 
and ophthalmoplegia. MJD type III presents slow disease progression and more peripheral signs, latest age 
at onset (40-70 years of age). In1983, Rosenberg added a fourth type, which is the rarest and includes 
MJD patients exhibiting Parkinsonic symptoms associated with the most representative symptoms of MJD. 
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MJD type V is also a rare form of ataxia and includes MJD patients resembling Hereditary Spastic 
Paraplegia, slow progression, onset of age vary from 10 to 70 with the average age of 30 (44, 46). 
 
1.3.3 MJD pathology 
Post-mortem brains from MJD patients revealed that neuronal degeneration of specific brain regions, such 
as the cerebellar dentate nucleus, pallidum, substantia nigra, subthalamic, red and pontine nuclei, select 
cranial nerve nuclei and the anterior horn and Clarke’s column of the spinal cord (51-53). Accordingly, the 
majority of MJD patients’ brains with more than 15 years of disease presented reduced brain weight 
compared to the brain of individuals without medical histories of neurological or psychiatric diseases (51). 
 
Figure -2. Brain region affected in MJD (red colour) STN: subtalamic nucleus, GP: globus pallidus, RN: red nucleus, SN: substantia nigra, PN: pontine nucleus, 
DN: dentate nucleus, LCN: lateral cuneate nucleus, CB: cerebellar cortex. 
 
Similar results were found in histopathological analysis of MJD transgenic mice brains, that revealed cell 
loss and/or atrophy in the lateral dentate (LD), vestibular (Ve) and pontine (Pn) nuclei, thalamus (Th) and 
substantia nigra (SN) as happened in MJD patient’s brains (54). MJD transgenic mice brains also showed 
astrogliosis in the Ve, SN and Th. Ataxin-3 aggregates were also found in the cytoplasm (perinuclear region) 
of several MJD affected brain regions, namely the LD, SN and Pn.  
Later on, pathoanatomical analysis of MJD brain demonstrated a widespread damage in neural cells of the 
cerebellum, thalamus, midbrain, pons, medulla oblongata and spinal cord. Systematic 
immunohistochemical study of serial thick brain section of MJD patients revealed axonal ATXN3 aggregates 
in fiber tracts which are known to undergo neurodegeneration in MJD (52-58).  A well-known pathological 
sign of MJD is intranuclear neuronal inclusions that consist of ATXN3 misfolded aggregated protein, 
ubiquitin, molecular chaperones and proteasomal components (59, 60). 
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1.3.4 MJD genetics 
Using genetic linkage analysis, MJD was mapped to the long arm of chromosome 14 (14q24.3-q32) in 
1993 (61). One year later, Kawaguchi and collaborators cloned the MJD1/ATXN3 gene (8). This gene was 
described as containing 11 exons, spanning a genomic region of about 48 kb, the (CAG)n tract being 
located at exon 10 (62). Normal CAG repeat ranges in the WT alleles between 12- 44; mutated alleles, with 
full penetrance, range between 52-86 repeats (63). Individuals carrying Intermediate CAG repeats, with the 
length of 45-51, may or may not manifest the disease. As expected, the presence of CAG tract expansion 
(mutation) was verified only in patients (64). 
 
1.3.5 MJD protein: Ataxin-3 (ATXN3) 
The ATXN3 gene encodes ataxin-3, a 42 KDa protein. ATXN3 is evolutionarily conserved in mice (65), rat 
(66), chicken (67), C. elegans (68), plants and other organisms. However, the long polyQ (CAG) tract is 
specific to humans, since it is nearly absent in other species such as mouse (6 Q) and C. elegans (1 Q). 
The human ATXN3 protein has a conserved N-terminal region, named Josephin domain (1-198 aa) that 
contains the catalytic triad of aminoacids: cysteine (C14), histidine (H119) and asparagine (N134). This 
domain is followed by two or three (in isoforms 1 and 4) ubiquitin-interacting motifs (UIMs), depending on 
the protein isoform. ATXN3 also contains a conserved nuclear-localization signal (NLS) (69). The polyQ 
stretch of variable length that is associated with different protein isoforms is located at the C-terminus of 
the protein (70, 71), whose expansion is intrinsically related with MJD. So far, four different variants of 
isoforms of ataxin-3 have been described: isoform 1 (NP_004984) has 361 aa, with a hydrophilic C-
terminal region and corresponds to the clones MJD1-1 and MJD5-1. Isoform 1 (3 UIMs) is the most 
abundant ATXN3 isoform in the brains of patients and transgenic mice. The second isoform (P54252) is 
formed by additional 4 a.a from isoform 1 and has a distinct C-terminal region compared with the first 
isoform, it is hydrophobic in nature and resembles to the clone MJD2-1 (72). Isoform 3 matches to the 
MJD1a variant (S50830), containing 349 a.a. The third variant particularly lacks 16 a.a due to a premature 
stop codon, compared with the second isoform (8). At last, isoform 4 (NP_1093376) contains less 55 a.a 
than isoforms 1 due to the lack of exon 2 in the H2 clone (62). This final variant lacks the catalytic amino 
acid (Cys14) which is essential for the deubiquitylating activity of ATXN3 against polyubiquitin chains. It 
remains to be defined which one of these variants is more relevant in the disease context. 
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Ataxin-3 is detected in the cytoplasm as well as nucleus and it is associated with the nuclear matrix, 
endoplasmic reticulum (ER) and mitochondria (60, 69, 73). Both the normal and pathogenic ATXN3 
proteins were expressed throughout the body and in all regions of the brain, including areas generally 
spared by the disease. Since embryonic life stages, the homologous of human ataxin-3 proteins are widely 
expressed in C. elegans and mouse (65, 68).  
 
A well-known function of ATXN3 is its deubiquitylating (DUB) activity which was described under in vitro 
conditions (71). The primary role of ATXN3 was proposed to be to deubiquitylate the substrate in order to 
facilitate proteasome degradation (74). Ataxin-3 also interacts with other proteins involved in (i) 
transcriptional regulation, (ii) cell structure and motility, and (iii) in the ubiquitin-proteasome pathway (UPP) 
and molecular chaperones. Moreover, histone ubiquitylation results in heterochromatin relaxation and 
assembly of transcription complexes on the promoter, and ubiquitylation of TF enhances their 
transcriptional activation function (75). Therefore, deubiquitylating enzymes like ataxin-3 can also modify 
transcriptional regulation through the removal of ubiquitin from histones. However, the biological 
consequence of this function has not been extensively characterized and the cellular substrates of ataxin-3 
remain unknown. 
1.4 Animal models (mouse) of MJD 
Since 1996, eight mouse animal models have been generated to understand the molecular mechanisms 
underlying MJD and to develop therapies (76-83), but so far, there is no treatment to delay the onset or 
cure the disease. Besides mouse, rat, C. elegans, cell culture and Drosophila models have also been used 
in MJD research. Apart from being a mammal, mouse models also have the greatest advantage of being 
close to humans at the genomic, anatomical, and physiological levels (84). A brief description of the mouse 
models generated so far is provided below (Table 2).  
Table -2: Mouse models of MJD. 
Transgene Promoter CAG 
repeat 
size 
Expression 
pattern 
Aggre
gates 
Neurodegener
ation 
Onset of 
illness 
 Phenotype  
Reference 
MJD1a cDNA 
total and C-
terminal 
L7 (Purkinje 
Cells) 
79 Purkinje 
Cells 
No Yes 4 weeks ataxia; gait disturbance; 
absence of elevation of the 
front paws. 
Ikeda et al., 
1997 
yeast artificial 
chromosome 
(YAC) with 
ATXN3 
ATXN3 64, 67, 72, 
76e, 84 
ubiquitous Yes Yes 4 weeks weight loss; hypotonia;  
tremor; inability to correct 
geotaxis. 
Cemal et al., 
2002 
cDNA MJD1a mouse prion 
protein 
71 ubiquitous Yes decreased TH-
positive neurons 
in substantia 
nigra 
 
8 weeks 
weight loss, premature 
death, incoordination; loss 
of strength in the limbs 
 
Goti et al., 
2004 
cDNA MJD1-1 murine prion 
protein 
15, 70, or 
148 
ubiquitous Yes ND 6 weeks tremor, wide-based 
hindlimbs, weight loss, 
reduced activity; 
Bichelmeier U 
et al.,2007 
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MJD1a CDNA 
total and C-
terminal 
murine prion 
protein 
79 ubiquitous Yes No 5 weeks incoordination; hypoactivity;  
ataxia; weight loss; 
reduction in the pelvic 
elevation  
Chou et al., 
2007 
cDNA MJD1-1 murine prion 
protein /Tet-
Off 
77 ubiquitous Yes Purkinje Cells 9 weeks reduced anxiety, 
hyperactivity,  
incoordination, smaller 
increase in weight 
Boy J et al., 
2009 
cDNA MJD1-1 huntingtin 
mouse 
148 ubiquitous No Purkinje Cells 48 weeks hyperactivity in early stages 
of  
disease, motor 
incoordination and 
amendment in motor 
learning in advanced 
disease 
Boy et al., 
2010 
cDNA MJD1-1 CMV 
(cytomegalov
irus) 
83 and 94 ubiquitous Yes astrogliosis and 
neuronal atrophy 
16 weeks incoordination Silva-Fernandes 
et al., 2010 
cDNA MJD1-1 CMV 
(cytomegalov
irus) 
135 biquitous Yes    loss of strength in the 
limbs, incoordination, 
weight loss, tremor, loss of 
hindlimb tonus, 
spontaneous locomotor and 
exploratory  activity 
decrease 
 
Silva-Fernandes 
et al., 2013 
 
In our lab, Silva-Fernandes and colleagues generated a novel transgenic mouse model for MJD, carrying 
the repeat tract coding for 83 polyglutamines, using a human cDNA (isoform 1, MJD1-1 clone) under the 
control of the pCMV (cytomegalovirus) promoter. Recently in 2013, Silva-Fernandes, et, al. generated a 
novel mouse model to study MJD pathogenesis and for pre-clinical trials, using a human cDNA, under 
regulation of the CMV promoter, carrying a 135Q repeat in coding region of ataxin-3.This new model 
recapitulates the disease by mimicking disease-like features such as ubiquitious expression, protein 
aggregation, loss of strength in limbs from 6 weeks, balance deficit from 8 weeks, swimming 
incoordination and shorter step length  from 12 weeks, body weight loss, tremors, limb clasping, loss of 
hind limb tonus, spontaneous locomotor and exploratory  activity decrease from 14 weeks. This model 
could be used for dissecting the cellular and molecular events in the pathogenesis of MJD as well as to test 
therapeutic strategies for this disorder.  
 
1.5 Rationale of pre-clinical trial drug targets 
1.5.1 Mitochondrial stabilization and reduction of oxidative stress 
Reduced concentrations of creatine, phosphocreatine (85) and mitochondrial electron transport enzymes 
(cytochrome C oxydase I) (86), and elevation in mtDNA deletion (87) have been observed in the basal 
ganglia and leucocytes of HD patients and in HD postmortem tissues, reinforcing the idea that oxidative 
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stress and mitochondrial dysfunction could be implicated in polyQ pathogenesis. Moreover, it was recently 
shown that mtDNA damage can be an early biomarker for HD. Interestingly, observations from the 
transgenic MJD mouse models  and MJD patient samples also showed a decrease in mtDNA copy number 
(89) and accumulation of mtDNA 3867bp deletions (88) in the initial stages of this disease. Downregulated 
PGC-1α (mediator of mitochondrial biogenesis), lower lymphocyte mitochondrial membrane potential and 
calcium loads have also been observed in HD patients and in HD animal models (90, 91). Isolated 
mitochondria from striatum cells expressing mutant htt showed induced mPTP opening and disruption of 
mitochondrial calcium homeostasis (92, 93). Comparing mitochondrial respiratory function between R6/2 
mice with 12 weeks of age and transgenic animals with 12 months, the latest showed higher respiratory 
control ratios and exhibited increased resistance to calcium loading; however when challenged with energy-
demanding stimuli, the neurons from this old mice are more vulnerable to calcium deregulation (94).  All 
together, these studies indicate that mitochondrial impairment and energy dysfunction might play a role in 
polyQ disorders, and that any treatment that might serve to buffer intracellular energy stores may delay the 
onset and/or progression of poly Q pathogenesis. 
Increased levels of 8-hydroxydeoxyguanosine (8- OHdG), an oxidized DNA marker, (95), lipid peroxidation 
markers (96) and decreased levels of antioxidant enzymes SOD (97), oxidized form of glutathione, Zn/Cu-
superoxide dismutase (Cu/Zn-SOD) (98) are found in HD patients’ brains and mouse model of HD. 
Likewise, a study in MJD also showed a significant reduction in the ratio of GSH/GSSG and total 
glutathione content (GSH + 2x GSSG) in mutant MJD cells expressing full length Ataxin-3 with 78Q (89). 
Another study from HD cellular model suggested that oxidative stress could promote aggregation and cell 
death by impairing proteasomal function and by overexpressing HSP27, has anti apoptotic properties; they 
were able to suppress the toxicity of mutant htt (99).  All these evidences suggest that increased oxidative 
stress, metabolic deficits and mitochondrial abnormalities likely play a role in polyQ diseases. Therefore, 
therapeutic agents targeting these pathways could be beneficial to the patients.  
Treatment with creatine, a bioenergetics supplement, stabilized the MPT, prevented ATP depletion and 
increased protein synthesis in HD mouse model. Creatine treatment also ameliorated brain pathology and 
motor symptoms, lessened brain atrophy and the formation of intranuclear inclusions in mouse models of 
HD. A Phase II clinical trial of creatine was performed in HD patients in which biomarkers were assessed in 
serum of these patients. Creatine supplementation reduced the levels of 8OH2’dG. Moreover, the dosage 
of creatine used (8g/day) was demonstrated to be tolerable and safe to patients (100). Based on these 
results, a phase III clinical trial has been approved and is currently ongoing in several centers. These 
results strongly support the effectiveness of creatine as a neuroprotector. 
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1.5.2 Clearance machinery: Chaperone related protein turnover 
Molecular chaperones are so important to maintain the native protein conformation and most of the 
chaperons belong to the family of Heat Shock Proteins (HSPs) that have the ability to correct abnormal 
folding of expanded polyQ proteins and have a protective effect on polyQ aggregation and 
neurodegeneration (101, 102). It was recently shown that overexpressing HSC70 in cells and in a 
Drosophila model prevents polyQ toxicity by decreasing the amount of soluble oligomers and aggregate 
formation (103, 104) In a cellular model of SCA1, overexpression of the chaperone HDJ2/HSDJ was able 
to decrease ataxin-1 aggregation and overexpression of Hsp70 in a SCA1 mouse model was shown to 
suppress neuropathology and improve motor function (105, 106). On the other hand, genetically reducing 
the level of co-chaperone and ubiquitin ligase CHIP (C-terminus of Hsp70-interacting protein) in transgenic 
mouse models increased ataxin-3 microaggregation and MJD progression. So, increasing CHIP activity 
could be a possible therapy for MJD and other polyQ diseases (107). 
Hsp90-containing HSF-1 (regulator of the heat-shock response (HSR)) complexes present in the unstressed 
cells are dissociated during stressed conditions, allowing the dislocation of this TF to the nucleus where it 
initiates the expression of several molecular chaperones. This includes Hsp90, which through classic 
negative feedback loop mechanisms, contributes to terminate the stress response (108). Therefore, Hsp90 
by itself and/or associated with multichaperone complexes, is a major repressor of HSF-1. In that sense, 
pharmacologic inactivation of Hsp90 leads to overexpression of several molecular chaperones by activating 
the HSR via HSF-1 (108-109). Hsp90 is also ATP-dependent molecular chaperone and Hsp90 inhibitors 
mimic the unusual ATP structure that is adopted in the chaperone's N-terminal nucleotide-binding pocket, 
causing potent and selective blockade of ATP binding/hydrolysis and inhibit its chaperone function (110). 
The modification of neurodegeneration by HSF-1 has been shown in cells, Drosophila, C. elegans, mouse 
brain and slice culture models.  Moreover, Hsp90 inhibitors, such as 17-AAG or 17-DMAG, significantly 
reduced aggregate load and toxicity.  Despite its high potency, 17-AAG has been proved to have moderate 
toxicity and it also showed poor bioavailability and stability in several clinical trials (111). In contrast, 17-
DMAG, a more effective analog of 17-AAG (112), is more water soluble than 17-AAG, a feature that is 
advantageous for clinical purposes, and it can be administered orally (113). These studies provide good 
evidence of the beneficial role of increasing chaperone levels in polyQ diseases. 
 
1.5.3 Transcriptional regulation 
Histone deacetylases (HDACs) regulate fundamental cellular activities such as transcription and play a 
crucial role in homeostasis of protein acetylation in histones and other proteins. Both acetylation and 
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deacetylation of histone proteins plays a pivotal role in the epigenetic regulation of transcription and other 
functions in cells, including neurons (114). Acetylation and deacetylation of histone proteins is catalyzed by 
histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively, at Lys (K) residues. 
Changes between HATs and HDACs interaction alters the balance of histone acetylation levels, resulting 
remodeling chromatin structure. In general, increased levels of protein acetylation facilitate transcription 
factor interaction with specific gene promoters and activate gene expression through relaxed chromatin 
conformation.  HDACs often work as transcriptional repressors to silence gene expression and induce 
chromatin compaction through histone protein deacetylation. Consequently, inhibition of HDAC shifts the 
equilibrium towards enriched histone acetylation, chromatin relaxation and gene expression. A 
disproportion of HAT and HDAC activities could lead to disease states (115). 
 
Several studies demonstrated the presence of transcriptional co-activators such as CREB-binding protein 
(CBP), p300/CBP-associated factor (PCAF), sperm-specific basic nuclear protein 1 (Sp1), and TBP-
associated factor 4 (TAFII130) in inclusion bodies and their co-localization with polyglutamine proteins 
(116). Mutant proteins that contain the polyQ-rich domain inhibit histone acetylase activity of CBP/p300 
though protein-protein interactions, and lead to cellular toxicity (117). Counteracting hypoacetylation by 
deacetylase inhibitors or CBP overexpression reduces neurodegeneration (118). Histone deacetylase 
inhibitors such as suberoylanilide hydroxamic acid (SAHA) (119), sodium butyrate (SB) (120) and 
phenylbutyrate (121) have been shown to ameliorate motor phenotype in mouse models of HD, DRPLA 
and SBMA. Further, inhibition of histone H3 methylation by mithramycin presented increased lifespan, 
improved motor performance and striatal pathology in R6/2 mice (122). Rolipram also alleviated 
transcriptional dysregulation by increasing the phosphorylation and thus activity of CREB (123), and slower 
progression of neurological phenotype, increase in lifespan, and improve neuropathology in R6/2 HD mice 
treated with rolipram (124). All of the above evidence supports the hypothesis that an imbalance in histone 
acetylation may be a key process leading to transcriptional dysregulation in polyQ diseases. 
Valproic acid (VPA) has been used for epilepsy and bipolar disorder and it is one of the HDAC inhibitors. It 
was demonstrated that VPA has the potential to regulate gene transcription and to mediate neuronal 
protection by inducing the apoptosis-inhibiting gene bcl-2 (124) and by inhibiting the activity of glycogen 
synthase kinase-3 (125). Jiping and collaborators very recently showed that VPA could increase both 
histone H3 and histone H4 acetylation level and reduce the early apoptotic rates of cells without inhibiting 
the aggregation of mutant ataxin-3 proteins in MJDtr-Q68- expressing cells (126). Based on this, we 
expected that VPA could serve as a new treatment strategy for SCA3 and other polyQ diseases. 
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Table- 3: Therapeutic rationale of our pre-clinical trials  
Compound Target Pre -clinical trial phenotype 
effect 
Drug effect in other 
polyQ disease 
Therapeutic 
strategy 
 
 
Creatine 
 
 
Energy supplier 
 
 
Improvements in muscular strength 
parameter, motor coordination. 
Improves survival and 
motor performance and 
delays neuronal atrophy, 
reduced NI (HD). (127) 
Mitochondrial 
dysfunction/energy 
metabolism 
 
 
 
 
17-DMAG 
 
 
 
Hsp-90 inhibitor 
 
 
 
Improvements in motor coordination 
and balance 
 
Improved motor phenotype, 
Alleviated nuclear 
localization of mutant AR; 
reduced muscle atrophy, 
body weight loss rate; 
prolonged life span. (SBMA) 
(128) 
 
Clearance machinery: 
Chaperone related 
protein turnover, 
Autophagy  
 
 
Valproic acid 
 
 
HDAC inhibitor, GABA 
transaminase inhibitor 
 
 
At late stage 
 
Prolonged life span; 
improved open field activity 
(HD)(129) 
NI not discussed. 
 
Transcription regulation 
 
1.6 Aim of the thesis 
This project aims to evaluate the utility of using ATXN3 inclusions as biomarkers in preclinical trials using a 
mouse model of MJD, by correlating the effect of three pharmacological compounds - creatine, 17-DMAG, 
and valproic acid, at the behavioral and molecular molecular level. 
This will be achieved by (i) quantifying the nuclear inclusion load in facial nuclei (7N) and lateral reticular 
nucleus (LRT) of MJD treated vs. untreated mouse brains and (ii) correlating their effect at the level of 
motor phenotype (observed in preclinical trials previously performed by others from our mice team) with 
the effect on inclusions of the mutant protein.  
To evaluate the effect of the drug at molecular level 
Our team has previously developed a new MJD mouse model expressing human ataxin-3 with 135 
glutamines under the regulation of the CMV promoter – CMVMJD135 – that presents phenotypic, 
pathologic and genetic similarities with the human disorder, namely several reliable and quantifiable 
phenotypic markers that can be used in therapeutic trials (Silva-Fernandes et al, 2014). For this study, we 
used mouse brains removed after treatment with three pharmacological compounds: creatine, 17-DMAG, 
and valproic acid, and with the respective vehicle solutions (control groups). We analyzed the abundance of 
ATXN3-positive nuclear inclusions in two specific brain regions known to be affected in MJD patients and in 
the CMVMJD135 mice - facial nuclei (7N) and lateral reticular nucleus (LRT) – by immunohistochemistry 
(IHC) and quantified the inclusion load by stereological microscopy approaches. 
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2. MATERIALS AND METHODS 
 
 
2.1. Animals 
Animals from the creatine group had been treated with 2% of supplemented creatine diet (by Sara Duarte-
Silva), and sacrificed at 24 weeks of age. The second group of transgenic animals had been 
intraperitoneally injected with 25mg 17 DMAG /kg body weight three times per week (by Sara Duarte-Silva) 
and sacrificed at the age of 30 weeks. The third group CMVMJD 135 mice had been treated with valproic 
acid 200mg/kg (by Sofia Esteves) and sacrificed at 30 weeks of age. All control animals were fed with a 
normal diet or treated saline (0.9% NaCl). 
Table -4:  Illustration of experimental animal 
Compound No. Animals 
Tg- non 
Rx Tg+Rx 
creatine 8 3 5 
valproic acid 8 4 4 
17DMAG 8 4 4 
 
 
2.2. Mouse genotyping 
DNA was isolated from tail biopsy using the Puregene DNA isolation kit (Gentra Systems, Minneapolis, 
MN). After DNA isolation, a single PCR was performed using the following primers for the human ataxin-3 
cDNA (size of the product: 454 bp): TR6 (5’TAC ATC AAT GGG CGT GGA T 3’) and TR7 (5’ GAG GTC AAA 
ACA GCG TGG A 3’). As an internal PCR control, the mouse homologous Atxn3 gene (size of the product: 
800 bp) was amplified using the following primers: mmMJD54 (5’ GAC TCC AGA GAG CAC CTG 3’) and 
mmMJD89 (5’ GCT AGC TAG AGC TAC TTA TTG 3’). 
 
2.3. IMMUNOHISTOCHEMISTRY 
Preparation of paraffin brain sections 
Transgenic mice CMVMJD135 were anaesthetized and transcardially perfused with PBS followed by 4% 
paraformaldehyde (PFA). Brains were immersed and embedded in paraffin block; the paraffin-embedded 
blocks were cut at 4µm thickness on a microtome then the sections were transferred onto glass slides 
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suitable for immunohistochemistry (IHC). Slides were selected to perform IHC based on the evaluation of 
sagittal section of brain morphology by cresyl violet staining (mouse brain Paxinos 2nd edition). 
Immunostaining with anti-ataxin-3 antibody 
Slides were pre-warmed at 700C and deparaffinized or hydrated in the staining apparatus. Sections were 
incubated 20 minutes in pre boiled and cooled citrate buffer 1x in the microwave at low temperature and in 
3% H2O2 solution (panreac) to block endogenous peroxidase activity. After PBS 1X washing, the sections 
were immersed in to UV block (ultravision large volume detection system-thermo scientific). Slides were 
incubated with primary antibody 1H9 anti ataxin-3(1:1000 milipore) overnight at 4OC and then incubated 
with HRP conjugated anti-mouse secondary antibody (thermo scientific) and then streptavidin reagent 
((thermo scientific)). Followed by PBS T, PBS, Tris-HCL 0.05M wash, slides were incubated with DAB 
(sigma lifescience) substrate solution and counter stained by hematoxylin according to standard 
procedures and the section dehydrated; coverslip were mounted by mounting solution after wash with xilol 
solution. The mounted slides were observed the color of the antibody staining in the tissue sections under 
microscopy (17).  
Quantification of ATXN3-positive intranuclear inclusions 
Ataxin-3-positive inclusions in the facial nuclei and LRT either vehicle- or compound-treated animal brain 
(Creatine: n=3-4 for each condition, LRT- 6 to 9 slides per animal, 7N- 6-10 slides per animal),(17-DMAG: 
n=4- 4 for each condition, LRT- 4 to 7 slides per animal, 7N- 4 to10 slides per animal) (VPA: n=4 - 6 for 
each condition, LRT- 2 to 7 slides per animal, 7N- 2 to 7 slides per animal) were quantified and normalized 
for the total area assessed using the Olympus BX 51 stereological microscope and the Visiopharma 
integrator system software. 
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3. RESULTS 
 
 
3.1 CMVMJD 135 mice treated with creatine exhibit reduced abundance of intranuclear ataxin-3 inclusion 
in the lateral reticular nuclei and facial nuclei of the brain 
In order to analyze the ATXN3 inclusion load in the CNS, CMVMJD135 female mice treated with creatine 
were sacrificed at 24 weeks of age, and 4µm thickness brain section were prepared onto glass slides 
suitable for immunohistochemistry. By observing the presence of ataxin-3 inclusion in the facial nuclei (7N) 
and lateral reticular nuclei (LRT) of the brain under the microscope, brain section treated with 2% creatine 
transgenic mice exhibited less inclusion in the nucleus of cells when compared with transgenic littermates 
treated with normal diet (Figure 3A). To confirm this, inclusion load was quantified by stereological 
microscopy. CMVMJD135 mice treated with 2% Creatine exhibited significantly less inclusions (P=0.012) in 
the LRT region when compared with CMVMJD135 mice treated with normal diet (control). The facial Nuclei 
also showed a tendency for reduction of inclusion load (P =0.232) in neurons and massive Standard 
Deviation was observed in unsupplemented creatine group. (Figure 3B).  This result suggests that dietary 
creatine supplementation is effective in decreasing aggregation of mutant human ataxin-3 in the LRT and 
7N region of CMVMJD 135 mice. 
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Figure 3- : Intranuclear ATXN3 inclusion load in CMVMJD 135 mice treated with a normal diet and 2% creatine supplementation. A) ATXN3 inclusion positive 
cells in LRT and 7N at 24 weeks of age mice brain. The control group displayed a higher median number of inclusions than the creatine treated group in both 
regions. B) Stereological analysis: quantification of ATXN3 inclusions in the LRT region shows a significant (P<0.05) increase in inclusion load in the 
unsupplemented group (vehicle) compared with creatine supplemented group. The 7N region shows a trend for reduction in inclusion load when compared to 
the control group.  (*  P<0.05) 
 
 3.2. CMVMJD 135 mice treated with 17-DMAG did not exhibit a reduction in intranuclear ataxin-3 
inclusions in the lateral reticular nuclei or facial nuclei of the brain  
CMVMJD135 male mice were (previously) treated with 17-DMAG from 5 to 30 weeks of age and animals 
were sacrificed at 30 weeks. Brain sections were prepared for IHC in 4µm thickness and observed 
aggregation in 7N and LRT region under the microscope. The qualitative assessment did not reveal marked 
differences in ATXN3 aggregation in these two regions upon 17-DMAG treatment (Figure 4A). Consistently, 
the quantification of inclusion density revealed no difference between control and 17-DMAG treated 
transgenic mice in both regions (P=0.340 for LRT, P= 0.476 for 7N) (Figure 4B).  
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Figure 4- : Intranuclear inclusion load in CMVMJD 135 mice treated with vehicle (saline), 17-DMAG. A) ATXN3 inclusion positive cells in LRT and 7N at 30 weeks 
of age. Differences were not seen between the control group and treatment group in both regions. B) By stereological analysis, quantification of ATXN3 inclusion 
in the LRT and 7N region did not show significant differences in inclusion load in the 17-DMAG treated group compared with the saline group.  
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3.3. Transgenic mice treated with Valproic acid (VPA) showed a trend towards less inclusion load than the 
saline-treated group. 
CMVMJD135 male mice were (previously) treated with VPA since 5 to 30 weeks of age and animals were 
sacrificed at 30 weeks. Brain sections were fixed with PFA and cut into 4µm thickness for IHC. Observation 
of inclusion in the 7N and LRT regions under the microscope did not reveal marked differences between 
groups (Figure 5A). Quantification of inclusion by stereological microscopy revealed a tendency for 
reduction of inclusion load between vehicle and VPA treated transgenic mice in the LRT region (P=0.060) 
and no differences in the 7N region (P=0.511) (Figure 5B). 
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Figure 5- : ATXN3 intranuclear inclusion load in CMVMJD 135 mice treated with vehicle and VPA. A) ATXN3 inclusion positive cells in the LRT and 7N at 30 
weeks of age. Marked differences were not seen by visual observation between the control and treatment group. B) Quantification of ATXN3 inclusion load 
showed a trens towards reduction in inclusion density in CMVMJD 135 mice treated with VPA compared to the saline treated group, but only in the LRT region.  
 
Table -5: A brief summary of the results obtained for the three compounds  
Treatment LRT 
 
7N 
Creatine p=0.012 
n=3-4 animal/group 
slides=6-9/animal 
 
p=0.232 
n=3-4 animal/group 
slides=6-10/animal 
 
17-DMAG p=0.340 
n=4 animal/group 
slides=4-7/animal 
 
p=0.476 
n=4 animal/group 
slides=4-10/ animal 
 
VPA p=0.06 
n=4-6 animal/group 
slides=2-7/animal 
 
p=0.511 
n=4-6 animal/group 
slides=2-7/animal 
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4. DISCUSSION 
 
 
In this study, we have devised strategies for efficiently assessing therapeutic efficacy of compounds in 
molecular level in MJD mouse models. For this study we used a new mouse model expressing human 
ATXN3 with an increased number of glutamine residues -135Q (78). This novel model mimics several 
features of the human disease quite well at the behavioral and molecular level.  
 
Since the discovery of NIs, it was thought that NI formation could be important to both pathogenesis and 
differential neuronal vulnerability in each polyQ disease. Sometimes, however, the connection between NIs 
and vulnerability is not clear, as they are not always associated with each other. For example, transgenic 
mice expressing a fragment of mutant htt showed very large numbers of NIs but with less 
neurodegeneration than mice expressing full-length mutant htt which undergo significant striatal 
degeneration without many NIs (54). 
 
Our first target of pre- clinical trial compound is creatine. Generally, the mitochondrial isoform of creatine 
kinase and its substrates, creatine and phosphocreatine, organize a system and regulate energy 
homeostasis in the brain (130). The proposed role of creatine supplementation for neuroprotection is 
buffering intracellular energy by increasing phosphocreatine levels and inhibiting activation of mitochondrial 
permeability transition (MPT), thus leading to inhibition of necrotic and apoptotic cell death (131). Brdiczka 
and colleagues suggested that mitochondrial creatine kinase involved in a functional interaction between 
the inner membrane adenylate translocator, and outer membrane voltage dependent anion channel, which 
are thought to be components of the MPT (132). Mitochondrial creatine kinase becomes stable in an 
octomeric form upon creatine administration, which then inhibits activation of the MPT (133). Creatine 
administration also results in increased ADP concentrations, which inhibit the activation of the MPT (131).  
Involved in a functional interaction 
 
The hypothesis of impairment of energy metabolism due to the mitochondrial dysfunction in polyQ 
diseases (34) provided the rationale for testing the therapeutic effects of creatine in CMVMJD135 mouse. 
Treatment of CMVMJD135 mice with creatine markedly improved limb strength at 6 weeks of age tested 
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by hanging wire test. Creatine treatment also had positive effects in the balance beam performance.  At 22 
and 24 weeks of age creatine-treated CMVMJD135 mice had better motor co-ordination, assed by motor 
swimming test. Moreover, creatine treatment was able to delay the onset of foot-dragging phenotype than 
unsupplemented creatine group, also delayed the disease progression by 12 weeks. (Sara Duarte-Silva, 
unpublished data). At the molecular level analysis, our IHC analysis showed a reduction in the nuclear 
aggregate load in the facial nuclei and LRT (39% less) comparable to CMVMJD135 mice fed with a normal 
diet. So in our pre-clinical trial with creatine, there was a direct correlation between the amelioration of the 
motor phenotype with the effect on the amount of inclusions of the mutant protein.  
Interestingly, it has been also shown in the R6/2 HD mouse model that oral administration of creatine 
inhibits huntingtin aggregation in brain slice culture (134) and increases survival and ameliorates motor 
deficit in HD mice (127). Creatine also enhanced Purkinje cell survival in a transgenic mouse model of 
spinocerebellar ataxia type 1 (135). Furthermore, the efficacy of creatine in phase II clinical trials with HD 
patient strongly supports the effectiveness of creatine as a neuroprotector. Therefore, a phase III trial is 
currently ongoing in various centers. Creatine administration may therefore be useful in therapy of polyQ 
disease. So far the mechanism of action of creatine upon protein aggregation is not clear. We hypothesize 
that creatine may enhance the misfolded and aggregated protein clearance via increasing the efficiency of 
the proteasome and protein degradation pathways, perhaps through increased availability of energy to 
maintain these processes.  
The second compound tested by our group in a pre-clinical trial, 17-DMAG, is proposed to reduce protein 
aggregation via elevated chaperone expression and proteasome activity. Chronic 17-DMAG treatment 
showed positive effects in the motor swimming test, rotarod and balance beam test and delayed the onset 
and progression of the foot-dragging phenotype CMVMJD135 mice, delaying the onset of key symptoms by 
approximately 8 weeks, which represents approximately 9% of the median C57Bl/6 normal lifespan 600 
days), and to a lesser extent the foot-dragging (6 weeks, 7% of the lifespan) (136). 
In contrast to these previous findings (136), our recent results revealed no reduction in the nuclear 
aggregate load in the 7N and LRT regions. . Overall, for 17-DMAG treatment in CMVMJD135 mice we did 
not observe a direct correlation between the amelioration of motor phenotype and intranuclear inclusions 
as a molecular biomarker, at least in these in these brain regions. However, administration of 17-DMAG 
was described to reduce the number of monomeric and nuclear-accumulated mutant AR and to improve 
motor performance without detectable toxicity in a SBMA mouse model (137).  It has been demonstrated 
in vitro in SBMA that 17-DMAG significantly increases the HSP70 and HSP40 expression level and 
decreased mutant AR, even when induction of HSP70 was blocked. This result strongly suggests that 17-
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DMAG contributes to mutant AR degradation through the inhibition of Hsp 90, with or without induction of 
Hsp 70 (137). Currently, phase I clinical trials with 17-DMAG are ongoing for some types of solid tumour, 
to test dosage, toxicity, pharmacokinetics and pharmacodynamics, therefore this compound has some 
possibility of entering the market soon for these indications. Further clinical studies will be need for 
neurodegenerative diseases, among which MJD. 
 
Deregulation of transcription due to the alteration of histone acetylation and deacetylation provided the 
rational for testing therapeutic effects of Valproic acid (VPA) in CMVMJD135 mouse. Results from our IHC 
analysis show that administration of VPA (200mg/kg) does not inhibit the nuclear accumulation of 
insoluble mutant Ataxin-3 in the LRT region. This is consistent with a previous publication in which it is 
described that administration of VPA increased H3 and H4 acetylation levels and reduced the early cell 
apoptotic rate without inhibiting the aggregation of mutant ATXN3 protein in vitro (138). CMVMJD135 mice 
treated with VPA showed minor phenotypic effects at late stages of the disease. No analysis was made 
beyond age of 24 weeks, which precludes more clear conclusions on the efficacy of the compound. 
Although it has been demonstrated in a SCA3 Drosophila model that VPA rescued polyQ-induced 
phenotypic abnormalities, no mention is made to effects on aggregation (126). However, histone 
acetylation and deacetylation can also regulate expression of heat shock proteins (HSPs) including HSP70. 
As an HDAC inhibitor, VPA could promote the expression of HSP70, that suppresses neuropathology and 
improve motor function in SCA1 mice, and extends the life of wild-type flies (139, 141). Based on this data 
and on the evidence we have for effects in aggregation, we suggest that VPA is a potential therapeutic 
agent for MJD, requiring further study. 
 
As mentioned above, CMVMJD mice treated with creatine had amelioration since early disease stages; our 
IHC results also suggest that creatine treatment reduces the neuronal inclusion density in the LRT and 7N 
region, which is directly correlated with the motor phenotype amelioration. So, creatine is a potential 
therapeutic compound at molecular and behavioral level in MJD. Another compound, 17-DMAG, showed 
amelioration since an inter mediate disease stage. Molecular level analysis did not show any differences 
between treated and non-treated transgenic mice group regarding neuronal inclusions in the LRT and 7N 
brain regions, although reduction in inclusion load in the PN and a phenotypic amelioration had previously 
observed by our team, in several behavioral paradigms.  Thus for this compound there was no direct 
correlation of phenotype amelioration effect with intra-nuclear inclusion load in the LRT and 7N regions.  
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CMVMJD135 mice treated with Valproic acid showed a tendency towards reduction of inclusion load in the 
LRT and no reduction in inclusion load in the 7N brain regions; phenotype amelioration was observed only 
at a late stage. So, this compound showed good effects on a molecular readout even though it exhibited a 
very mild phenotype amelioration only at late stages.  
Globally, our results suggest that there is no direct correlation between the aggregate load in these regions 
of the brain of the CMVMJD135 mice and the amelioration of the phenotype observed with the chronic 
treatment with different compounds. 
 
  
 
4.1. Future Perspectives 
Regarding the identification of potential effects of the candidate therapeutic compounds at the molecular 
level in the CMVMJD135 mouse model, we need to further validate our hypothesis about creatine, 17-
DMAG and VPA in other brain regions. It would be interesting to perform a similar study in another brain 
region, such as the dentate or pontine nuclei, for creatine and VPA. Moreover, other pre-clinical trials with 
additional compounds such as lithium and novel Hsp90 inhibitors provided by a pharmaceutical company 
are still ongoing in our lab, for which studies at molecular level will also be required.  
Inclusion in non-CNS tissues were also observed in HD models. So, it would also be interesting to study 
inclusion in non-CNS tissues of CMVMJD135, particularly in tissues we have identified as affected, such as 
the skeletal muscle. 
Finally, since the intranuclear inclusions we observe in the brain of patients and mouse models are thought 
to be a final product of a complex aggregation pathway, it would be essential to study as potential 
biomarkers ATXN3 aggregation species situated more upstream in this pathway, such as soluble 
oligomers, which may be more relvant in terms of pathogenesis. 
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5. CONCLUSIONS 
 
 
Several studies implicates impaired energy metabolism due to the mitochondrial dysfunction in the 
pathogenesis of neurodegenerative diseases. Our results suggest that dietary creatine supplementation is 
effective in decreasing aggregation of ataxin-3 in the LRT and 7N regions of the brain of CMVMJD135 mice. 
Although creatine is an energy supplier it lessened the inclusion load in affected brain region. Therefore, for 
creatine supplementation we observed treatment efficacy at the molecular as well as behavioral level. As 
for other polyQ diseases, supplementation of creatine is thus a promising strategy for MJD therapy.  
17-DMAG treated mice did not show marked reduction of neuronal inclusions in the LRT and 7N region of 
the CMVMJD135 mouse model. However, this molecule has been previously shown to have positive 
beneficial effects for MJD treatment at the behavioral and molecular level. So, 17-DMAG is also a 
promising therapeutic compound for MJD but its effects on ATXN3 aggregation don’t seem to extend to all 
brain regions.  
CMVMJD mice treated with VPA showed mild phenotype amelioration at late stages of the disease, but only 
a trend towards reduction in the inclusion density was observed, restricted to the LRT region.  
Overall, our results suggest that there is no direct correlation between the aggregate load in the LRT and 
7N regions of the brain of the CMVMJD135 mice and the phenotypic effects observed with the chronic 
treatment with different compounds. 
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